Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Vir Biotechnology, Inc. before investing.

In this article, we go over a few key elements for understanding Vir Biotechnology, Inc.’s stock price such as:

• Vir Biotechnology, Inc.’s current stock price and volume
• Why Vir Biotechnology, Inc.’s stock price changed recently
• Upgrades and downgrades for VIR from analysts
• VIR’s stock price momentum as measured by its relative strength

About Vir Biotechnology, Inc. (VIR)

Before we jump into Vir Biotechnology, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company’s preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Want to learn more about Vir Biotechnology, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Vir Biotechnology, Inc..

Vir Biotechnology, Inc.’s Stock Price as of Market Close

As of February 25, 2026, 4:00 PM, CST, Vir Biotechnology, Inc.’s stock price was $10.000.

Vir Biotechnology, Inc. is up 5.37% from its previous closing price of $9.490.

During the last market session, Vir Biotechnology, Inc.’s stock traded between $9.760 and $10.940. Currently, there are approximately 139.22 million shares outstanding for Vir Biotechnology, Inc..

Vir Biotechnology, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Vir Biotechnology, Inc. Stock Price History

Vir Biotechnology, Inc.’s (VIR) price is currently up 34.41% so far this month.

During the month of February, Vir Biotechnology, Inc.’s stock price has reached a high of $10.940 and a low of $6.860.

Over the last year, Vir Biotechnology, Inc. has hit prices as high as $10.290 and as low as $4.155. Year to date, Vir Biotechnology, Inc.’s stock is up 65.84%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Vir Biotechnology, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of February 24, 2026, there were 0 analysts who downgraded Vir Biotechnology, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Vir Biotechnology, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Vir Biotechnology, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Vir Biotechnology, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Vir Biotechnology, Inc. (VIR) by visiting AAII Stock Evaluator.

Relative Price Strength of Vir Biotechnology, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of February 24, 2026, Vir Biotechnology, Inc. has a weighted four-quarter relative price strength of 16.73%, which translates to a Momentum Score of 85 and is considered to be Very Strong.

Want to learn more about how Vir Biotechnology, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Vir Biotechnology, Inc. Stock Price: Bottom Line

As of February 25, 2026, Vir Biotechnology, Inc.’s stock price is $10.000, which is up 5.37% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Vir Biotechnology, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.